Orchestra BioMed Holdings, Inc.

NASDAQ:OBIO

Biotechnology

Healthcare
$7.46 +1.16%

+$0.05 today

Market cap
$587.14M
Beta
0.50
P/E (TTM)
-2.8
EPS (TTM)
-$1.42
52W Low $2.20High $5.42

Volume 1.20M

Average 0.22M

Income Statement

Follow revenue through to earnings.

Revenue

$33.48M

FY 2025 · Annual

+1169.2% YoY

Operating Income

-$51.81M

FY 2025 · Annual

Net Income

-$52.70M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue(782K)3.53M2.76M2.64M33.48M
Cost of Revenue199K322K186K204K190K
Gross Profit(981K)3.21M2.57M2.43M33.29M
Gross Margin125.4%90.9%93.3%92.3%99.4%
Research & Development12.89M21.95M33.82M42.8M58.19M
Selling, General & Admin7.93M13.92M20.26M23.93M26.91M
Operating Expenses20.82M35.87M54.08M66.74M85.1M
Depreciation & Amortization181K222K287K308K327K
EBITDA(21.91M)(33.39M)(48.83M)(60.72M)(51.23M)
EBITDA Margin2801.3%-945.0%-1769.3%-2301.6%-153.0%
Operating Income(21.8M)(32.66M)(51.51M)(64.3M)(51.81M)
Operating Margin2787.6%-924.3%-1866.2%-2437.5%-154.7%
Interest Income050K3.85M3.36M0
Interest Expense927K0001.15M
Other Income / Expenses(1.22M)(951K)2.39M3.28M(894K)
Income Before Tax(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Pre-Tax Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
Income Tax Expense00000
Net Income(23.01M)(33.61M)(49.12M)(61.02M)(52.7M)
Net Margin2943.0%-951.3%-1779.7%-2313.3%-157.4%
EPS (Basic)(0.02)(1.32)(1.48)(1.66)(1.38)
EPS (Diluted)(0.02)(1.32)(1.48)(1.66)(1.38)
Weighted Avg Shares20.45M25.47M33.23M36.82M38.39M
Weighted Avg Shares (Diluted)20.45M25.47M33.23M36.82M38.39M

OBIO Earnings Waterfall · TTM

NASDAQ:OBIO · Revenue to Net Income

Key Ratios

EPS$-1.42
Gross Margin76.3%
Net Margin-5881.2%
P/E Ratio0.5
P/S Ratio430.5

Analysis

$32.7M of revenue converted into -$54.6M of net income for the selected period. Gross margin is 76.3% and net margin is -5881.2%, showing how much revenue survives after costs and taxes. EPS is $-1.42, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
SC 13D/ASC 13D/A filingNov 12, 2026
10-QQuarterly reportNov 10, 2026
4Statement of changes in beneficial ownershipNov 9, 2026
4Statement of changes in beneficial ownershipNov 9, 2026

How much revenue does OBIO generate?

Orchestra BioMed Holdings, Inc. (OBIO) reported $33.48M of revenue in fiscal 2025.

Is OBIO profitable?

Orchestra BioMed Holdings, Inc. (OBIO) reported -$52.70M of net income, with a net margin of -157.4%.